MINUTES
INSTITUTIONAL BIOSAFETY COMMITTEE
DATE: February 13, 2026

Attendance: # 10 **Voting Members Present**: # 9

Called to Order: 10:02 a.m.

Name	Expertise	Present
Linda Cassidy, MS	Non-Voting Member	X
Sue Gotta, MS	rDNA; Select Agents	X
Gerald Grunwald, PhD	rDNA; Biochemistry; Cellular & Developmental Biology	X
Douglas C. Hooper, PhD	rDNA; Immunology; Gene Transfer	X
Botond Igyarto, PhD	Microbiology	X
Loretta Kelly, Esq.	Non-affiliate Community Member	
Kathleen "Kitty" Kono	Non-Affiliate Community Member	X
Phil LaTourette, DVM	Laboratory Animal Sciences	X
Sara Meyer, PhD	Cancer Biology	X
Fabienne Paumet, PhD	Cellular Biology & Biochemistry	X
Drake Stierman	Safety Officer	
Megan Watson, MS	Lab Specialist	X

MINUTES REVIEWED:
Minutes of the December, 2025 meeting were presented for review.
Motion to Approve: Sara Meyer
Seconded: Phil LaTourette
Total = #9; For-#6, Opposed-#0, Abstained-#3

Minutes of the January, 2026 meeting were presented for review.
Motion to Approve: Sue Gotta – with clarifications made to the "Other Business" section for specific ABSL3 and BSL3 scheduling.
Seconded: Phil LaTourette
Total = #9; For-#9, Opposed-#0, Abstained-#0

The committee reviewed and approved the revised December and January minutes. The revisions incorporate the intent of the NIH guidelines and will be used going forward.

NEW PROTOCOLS:

1. **Principal Investigator: R.C.** IBC Control# 26-01-1005

Summary:
- This study involves the role of cytoskeleton actin in regulation of intracellular organelle movement in cells.
- This is an in vitro study.
- The principal risks identified were:
  - Human cell lines
  - Lentiviral vectors
- Containment has been set to BSL-2.

Committee Review:

- This protocol was reviewed under NIH Category E.
- The risks were adequately identified by the Principal Investigator, and appropriate mitigation was described in the protocol**.**
- Clarifications were requested.
- A motion was made and seconded to provisionally approve this protocol. The motion was unanimously approved.

ADMINISTRATIVELY APPROVED ITEMS:

The KSI database indicates the following items have been given administrative approval since our last meeting:

2/13/2026

Protocol #	PI - Initials	Form type	Comments
23-10-738	MN	Continuing Review	Not started - personnel changes only
22-03-490-1	DA	Continuing Review	Active - personnel changes only
21-11-457-1	DA	Continuing Review	Active - personnel changes only
24-01-782	CE	Continuing Review	Active - updated Protocol Summary abbreviations
21-11-459-1	AF	Continuing Review	Active - no updates, 3 yr review
25-03-936	EA	Amendment	Added Doxorubicin & Etoposide, previously approved, updated personnel
26-01-1009	JS	New	BAPN, Bleomycin, Streptozotocin, previously approved
23-07-708	BE	Amendment	Added Mitoxantrone, updated research location
22-12-621	MS	Continuing Review	Active - personnel changes only, open to enrollment
24-08-879	DK	Continuing Review	Active - updated personnel & research location
25-02-933	UG	Continuing Review	Active - clinical trial, open to enrollment, added location
25-01-923	JH	Continuing Review	Active - no updates
23-11-767	JC	Continuing Review	Active - no updates
23-08-711	JS	Continuing Review	Active - personnel changes only

OTHER BUSINESS:

- Gerald Grunwald welcomed two new members to the committee. Megan Watson is a Lab Specialist in our Microbiology Department. Drake Stierman is a Safety Officer in our Environmental Health & Safety Department.
- Gerald Grunwald confirmed that Question 4 in our protocols for Recombinant or Synthetic Nucleic Acid material administered or transferred to human subjects should be answered “Yes” for human gene therapy trials involving CAR-T recombinant DNA.
- Our Research Compliance group and Legal agreed with the committee that FDA authorized products which are Out of Specification (OOS) for commercial release and are used in the FDA’s Expanded Access Program (EAP), per NIH Guidelines Section III-C-1, do not need IBC approval.
- Sue Gotta confirmed our BL3 and ABL3 facilities on 7th floor BLSB and 6th floor JAH were commissioned. The next commissioning has been delayed until the first week of March. This will include our 3rd floor JAH ABSL3 and 5th floor BL3 labs.

Meeting Adjourned: 10:59 a.m.

Respectfully submitted for the IBC,

/s/Gerald Grunwald, PhD
Chair, Institutional Biosafety Committee

GG/lc